Green Cross Corporation

République de Corée


 
Quantité totale PI 182
Rang # Quantité totale PI 7 106
Note d'activité PI 2,8/5.0    97
Rang # Activité PI 7 142
Symbole boursier
ISIN KR7006280002
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

55 0
25 4
88 9
1
 
Dernier brevet 2024 - 5'-utr containing mrna construct...
Premier brevet 1989 - Hantaan virus strain rok84/105 a...
Dernière marque 2019 - VARIGREE
Première marque 2015 - ELGAMMA

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention 5'-utr containing mrna constructs with improved translation efficiency and vaccine compositions c...
Invention Novel liquid formulation for prevention or treatment of thrombotic disease. The present invention...
2023 Invention Pharmaceutical composition comprising heparan n-sulfatase with improved stability. The present in...
Invention Composition for treating of facial dysmorphism in mucopolysaccharidosis. A composition and a use...
Invention Cycloalkane-based lipid compound for delivering nucleic acids, and lipid nanoparticles comprising...
Invention Ionizable lipid and use thereof. The present invention relates to a novel ionizable lipid compoun...
Invention Composition for treatment of facial dysmorphism in mucopolysaccharidosis. The present invention r...
Invention Pharmaceutical composition for preventing or treating hemarthrosis. The present invention relates...
Invention Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same. The...
Invention Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives. The present inventio...
Invention Novel process for purifying heparan-n-sulfatase. The present invention is related to a method for...
Invention Lipid nanoparticles using cationic cholesterol for local delivery for nucleic acid delivery. The ...
Invention Novel liquid formulation for plasma protein. The present invention relates to a pharmaceutical fo...
Invention Novel liquid formulation for lyophilization of plasma protein. The present invention relates to a...
Invention Lyophilized formulation comprising a fusion protein including α-galactosidase a. The present inve...
Invention Liquid formulation comprising a fusion protein including α-galactosidase a. The present invention...
Invention Method for purifying factor xiii. Disclosed is a method of purifying factor XIII comprising (a) f...
2022 Invention Method for preventing or treating of hemathrosis. A pharmaceutical composition capable of exhibi...
Invention 5'-utr with improved translation efficiency, a synthetic nucleic acid molecule including the same...
Invention Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same. An anti-C...
Invention Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically ...
Invention A composition for treatment of hepatitis b comprising hbv specific antibody for combination with ...
Invention Method for purification of hemopexin and haptoglobin. The present invention relates to a method ...
2021 Invention Self-administration assistance device. The present invention relates to a self-administration ass...
Invention Coronavirus spike protein-specific antibody and use thereof. Provided are a coronavirus spike (S...
Invention Antibody specific to coronavirus spike protein and use thereof. The present invention relates to ...
Invention Adamts13 variant having increased escaping rate or activity against autoantibody. An ADAMTS13 mu...
Invention Adamts13 variant having increased escaping rate or activity against autoantibody. The present inv...
Invention Method for removing fxi when purifying plasma proteins. Disclosed is a method for removing facto...
Invention Method for production of varicella zoster virus surface protein antigen. A method for production...
Invention Method for production of varicella zoster virus surface protein antigen. The present invention re...
2020 Invention Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically...
Invention Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceuticall...
Invention Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt...
Invention Antibody to tigit and use thereof. The present invention relates to: an antibody to T cell Immun...
Invention Bispecific antibody specifically binding to gpnmb and cd3, and use thereof. A bispecific anti-GP...
Invention Conformational epitope of hepatitis b surface antigen and antibody binding specifically thereto. ...
2019 Invention Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bisp...
P/S Pharmaceuticals; drugs for medical purposes; medicines for human purposes; human vaccine prepara...
Invention Steric epitope of ceacam1, and anti-ceacam1 antibody, or fragment thereof, that specifically bind...
Invention Highly efficient anti-tfpi antibody composition. The present disclosure relates to a pharmaceuti...
P/S Pharmaceutical agents affecting metabolism for liver disease; biological preparations for liver ...
Invention Method and composition for treating hunter syndrome through cerebral lateral ventricle administra...
2018 Invention Factor viii or factor ix gene knockout rabbit, method for preparing same and use thereof. The pr...
2017 P/S Medicines for mucopolysaccharidoses; medicines for treating metabolism disorder; bacteriological ...
P/S Medicines for human purposes; pharmaceutical preparations.
P/S Pharmaceutical preparations for central nerve treatment; pharmaceutical preparations for diagnos...
2016 P/S Medicines for mucopolysaccharidoses; medicines for treating metabolism disorder, namely diabetes,...
P/S Medicines for mucopolysaccharidoses; medicines for treating metabolism disorder; bacteriological...
P/S Pharmaceuticals; pharmaceutical preparations for the treatment of neutropenia; pharmaceutical pr...
P/S Pharmaceutical preparations for the treatment of hemophilia; vial preparations for the treatment...
2015 P/S Pharmaceutical preparations, namely, Intravenous immunoglobulin (IVIG)